Chapter 15: Translation: Synthesis of Proteins

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Welcome to the Deep Dive.

Today we're journeying into, well, one of the most fundamental processes in our cells, how the blueprint of life, the DNA code, gets turned into the actual proteins that do all the work.

We're talking about translation.

It's absolutely central.

Right.

It's this molecular marvel where the genetic message becomes a real functional molecule.

So our mission today, we want to crack that genetic code,

meet the molecular machines involved, follow the protein assembly step by step, and really see how this whole process impacts health and disease, sometimes in quite surprising ways.

It really is a marvel of biochemical engineering, like you said.

Proteins are, well, they're the workhorses of the cell.

Absolutely everything depends on them.

Everything.

Pretty much.

Structure, enzymes, transport, defense, you name it.

And making them translation, that's the crucial final step.

Taking the information from DNA and putting it into action.

Without it, life as we know it just wouldn't work.

Okay.

Let's unpack this then.

It sounds like a big challenge.

Our genetic info, it's written in just four letters, right?

AUGC in the RNA message.

That's right.

But proteins are built from 20 different amino acids.

How does the cell translate between those?

Seems like you'd run out of codes.

That's exactly the decoding problem they faced.

You see, with only four bases, one base can't code for 20 things.

Two bases.

That only gives you what?

Four times four,

16 combinations.

Still not enough.

Right.

So the solution had to be a triplet code.

Three nucleotides in a row.

We call that a codon.

Specify one amino acid.

Ah, three.

So four times four times four.

Sixty -four possibilities.

Which is more than enough for the 20 amino acids plus signals for starting and stopping.

It gives you some redundancy.

Okay, that makes sense.

And who figured this out?

How did they crack the first part of the code?

Well, a huge breakthrough came from Marshall Nirenberg back in 1961.

It was quite elegant, actually.

Yeah.

He created a synthetic RNA molecule that was just uracil basis.

Just UUU.

Exactly.

Poly -U.

And he put this into a system that could make proteins, but without any cells.

And guess what protein it made?

Let me guess.

Something with just one amino acid.

Precisely.

It made a chain of only phenylalanine.

So that proved it.

The codon UU codes for phenylalanine.

And that just blew the doors open to figuring out the rest.

Wow.

Okay.

So we have these three -letter codons.

You mentioned start and stop signals.

Yes.

There's one specific codon, AUG.

It codes for the amino acid methionine, but it also acts as the start codon.

It tells the machinery,

okay, start reading the protein sequence here.

Crucial.

And it sets the reading frame.

Absolutely crucial.

And make sure all the following codons are read in the correct groups of three.

Get the frame wrong.

And the whole message becomes gibberish.

Right.

And then at the other end, you have three different stop codons, UAG, UGA, and UAA.

They don't code for any amino acid.

They just signal stop here.

Protein finished.

Like punctuation at the end of a sentence.

Okay.

So mRNA has the codons.

How does the cell actually read them and bring in the right amino acid building block?

Ah, that's where these amazing little molecules called transfer RNA or key RNA come in.

Yeah.

Think of them as molecular adapters or shuttles.

Yeah.

Each tRNA molecule has two important ends.

At one end, it carries a specific amino acid attached firmly.

At the other end, it has a sequence of three bases called the anticodon.

Anticodon.

So it matches the codon.

Exactly.

The anticodon base pairs perfectly with its complementary codon on the mRNA molecule.

So the mRNA codon says, I need leucine.

And the specific tRNA with the leucine anticodon comes in carrying leucine.

It's the physical link between the code and the amino acid.

That is incredibly neat.

Now I've heard the code described as both degenerate and unambiguous.

That sounds like it contradicts itself.

It does sound a bit contradictory at first glance, doesn't it?

But it's actually a key feature.

Degenerate just means that most amino acids are specified by more than one codon.

Oh, like leucine might have several different three -letter codes.

Exactly.

Leucine has six.

This degeneracy actually provides a buffer.

If there's a small mutation, a change in one DNA letter, it might change the codon, but maybe it still codes for the same amino acid.

So no harm done.

Okay.

That makes sense.

Protection.

So what about unambiguous?

Unambiguous means that any single codon only ever specifies one particular amino acid.

UUU always means phenylalanine.

It never means leucine or serine or anything else.

So the instructions are always clear, even with the redundancy.

Degenerate but unambiguous.

Got it.

Now this degeneracy raises a question.

If there are 61 codons that code for amino acids, do we need 61 different types of tRNA molecules, each with a unique anticodon?

Seems like you would.

Well, not quite.

Thanks to Francis Crick again and his wobble hypothesis.

Wobble?

Yeah, wobble.

He realized that the pairing between the third base of the codon on the mRNA and the first base of the anticodon on the tRNA isn't quite as strict as the other two positions.

There's a bit of flexibility or wobble.

So the third position can be a bit loosey -goosey.

Kinda.

For example, sometimes a modified base called hypoxanthine or I appears in the tRNA anticodon's first position, and I can actually pair with U, C, or A in the codon's third position.

Ah, so one tRNA could potentially read multiple codons that differ only in that third base.

Precisely.

Like for alanine, the codons GCU, GCC, and GCA can all be read by a single tRNA with the anticodon IGC.

This wobble means the cell needs fewer than 61 tRNAs to read the whole code.

It's more efficient.

Clever.

And critically, the code is read straight through, right?

Non -overlapping.

Absolutely non -overlapping.

Each nucleotide is part of only one codon.

Read GCA, then the next three, then the next three.

No skipping, no reading bases twice.

It ensures the sequence is read exactly as intended.

Okay.

So we have the code, the mRNA message.

We have the tRNA adapters bringing the right amino acids.

What's the actual machinery, the factory, where this all happens?

That would be the ribosome.

The ribosome is this incredible molecular machine, a complex made of ribosomal RNA or rRNA and proteins.

Made of RNA and proteins.

Yes.

And the RNA part is actually doing a lot of the catalytic work, which is fascinating.

It comes in two main pieces, a large subunit and a small subunit.

Okay.

And within the assembled ribosome, there are three key sites, like docking stations for the tRNAs.

There's the A site, the aminoacyl site, where the next tRNA carrying its amino acid arrives.

A for arriving.

You could think of it that way.

Then the P site, the peptidyl site, which holds the tRNA carrying the growing polypeptide chain.

P for polypeptide.

Exactly.

And finally, the E site, the exit site, where the now empty tRNA, having dropped off its amino acid, leaves the ribosome.

APE.

APE sites.

Okay.

But how does the tRNA get the right amino acid attached in the first place?

That seems critical.

Absolutely critical.

And that's handled by another set of essential enzymes, the aminoacyl tRNA synthetases.

That's a mouthful.

It is, but their job is vital.

There are 20 different synthetases, basically one for each type of amino acid.

Each one is incredibly specific.

It recognizes one amino acid and all the corresponding tRNAs for that amino acid.

So the synthetase for alanine only attaches alanine to alanine tRNAs.

Precisely.

It forms that covalent bond between the amino acid and its correct tRNA.

This charging step requires energy.

It uses ATP.

And here's another layer of quality control.

This charging step is the first major error checking point.

These synthetases are so accurate, they even have a proofreading function.

If they accidentally attach the wrong amino acid, they can usually detect it and cut it off.

Wow.

So checking before it even gets to the ribosome.

Yes.

Ensuring high fidelity right from the start.

And you mentioned a special tRNA for starting things off.

That's right.

The initiator methanol tRNAmit.

It's a specific tRNA carrying methionine that's designed just to recognize that AUG starts code on and kick off the whole process.

Okay.

Brilliant.

We've got the code, the adapters, tRNAs, the charging enzymes, synthetase, and the factory ribosome.

So how does it all come together?

Walk us through actually building a protein.

Right.

The process itself.

We usually break it down into three main stages.

Initiation, getting everything set up correctly.

Elongation, adding amino acids one by one to build the chain.

And termination, stopping the process and releasing the finished protein.

Initiation, elongation, termination.

Let's start with initiation.

Okay.

Initiation in our cells in eukaryotes.

It's quite complex, actually.

It involves a whole crew of protein helpers called eukaryotic initiation factors, or EIFs.

EIFs.

Yep.

And energy usually from GTP.

Essentially, these factors help bring together the small ribosomal subunit, the initiator methanol tRNA, and the mRNA molecule.

The ribosome needs to find the right starting point.

The AUG codon.

The right AUG codon.

In eukaryotes, it usually recognizes the five -foot cap structure on the mRNA first.

Then it kind of scans along the mRNA until it finds the start codon, often helped by a surrounding sequence called the COZAC sequence.

Once it finds the AUG and the initiator tRNA is bound, the large ribosomal subunit clamps down, the initiation factors leave, and everything's ready to go.

The initiator tRNA sits in the P site.

Okay.

That sounds like a precise setup.

What about in bacteria?

Is it different?

It is different in some key ways, yes.

Prokaryotic initiation uses a slightly modified methionine to start called formal methionine.

Their ribosomes are a bit smaller.

And importantly, their mRNAs don't have that five cap.

So how do they find the start codon?

They use a specific sequence on the mRNA before the start codon called the Shine -Delgarno sequence.

The small ribosomal subunit recognizes and binds directly to that sequence, positioning the ribosome right at the nearby AUG.

Shine -Delgarno.

COZAC sequence.

Different mechanisms.

Why are these differences actually important?

Ah, they're incredibly important clinically.

Because these differences between bacterial and human protein synthesis machinery allow us to design antibiotics.

Right.

Target the bacteria without harming our own cells.

Exactly.

Many common antibiotics work by selectively inhibiting bacterial translation.

For example, streptomycin can mess up bacterial initiation.

Tetracycline blocks the A site on the bacterial ribosome, so new tRNAs can't come in.

And you mentioned azithromycin earlier for Paul T's case.

Yes.

Azithromycin is a macrolide antibiotic.

Macrolides bind to the bacterial ribosome and essentially jam the machinery, preventing the ribosome from moving along the mRNA during elongation.

We'll get to that.

So exploiting these differences is a cornerstone of fighting bacterial infections.

Of course, we always need to be mindful some antibiotics can affect mitochondria, which have bacteria like ribosomes, but generally the selectivity is high.

That's fascinating.

And you mentioned initiation can be controlled by the cell, too.

Oh, yes.

It's a major control point.

For example, the hormone insulin can trigger signaling pathways that activate certain EIFs, boosting overall protein synthesis when growth is needed.

Makes sense.

Conversely, under stress conditions, like if the cell is starved of nutrients or infected by a virus, it can shut down translation initiation to conserve energy,

often by phosphorylating a key initiation factor, EIF2.

There are lots of intricate controls.

Okay.

So initiation sets the stage.

The first tRNA is in the P site.

What happens next?

That must be elongation.

Exactly.

Now the ribosome starts chugging along the mRNA, adding amino acids.

Think of it like reading the mRNA tape codon by codon.

Like a train on a track adding cargo at each stop.

That's a great analogy.

So step one of elongation

about the codon sitting in the ribosomes A site arrives.

It's escorted by an elongation factor called EEF1A in eukaryotes and GTP.

Crucially, this tRNA only binds firmly if its anticodon is a correct match for the mRNA codon in the A site.

If it fits, GTP is hydrolyzed, the elongation factor leaves and the correct aminoacyl tRNA is locked into the A site.

This codon anticodon matching is the second major error checking step.

Another checkpoint.

Very important for accuracy.

Step two, peptide bond formation.

Now you have the growing chain attached to the tRNA in the P site and the new amino acid on its tRNA in the A site.

The ribosome catalyzes the formation of a peptide bond between them.

The polypeptide chain is essentially transferred from the P site tRNA onto the amino group of the amino acid in the A site.

This reaction is catalyzed by peptidyl transferase activity,

which remarkably comes from the ribosomal RNA itself.

It's a ribosome.

The RNA is the enzyme.

Wow.

Okay.

So now the chain is longer and it's attached to the tRNA in the A site.

Correct.

Step three, translocation.

The ribosome now needs to move one codon down the mRNA to read the next instruction.

This movement is called translocation.

Another elongation factor, EEF2 in eukaryotes, also using energy from GTP hydrolysis, binds and causes a shift.

The entire ribosome moves three nucleotides along the mRNA.

So everything shifts over.

Exactly.

The tRNA in the P site, now empty without its amino acid, moves to the E site and exits.

The tRNA in the A site, now carrying the elongated polypeptide chain, moves into the P site.

And the A site is now empty again, positioned over the next codon, ready for a new amino cell tRNA to arrive.

The cycle repeats.

tRNA binds A site, peptide bond forms, ribosome translocates over and over.

Precisely.

Binding, peptide bond formation, translocation.

Binding, peptide bond formation, translocation, adding one amino acid at a time, moving down the mRNA.

And you mentioned antibiotics hit elongation too.

Tetracycline blocked the A site.

Right.

Chlorinphenicol can block the peptidyl transferase reaction.

And macrolides, like azithromycin, specifically inhibit that translocation step in bacteria.

And what about toxins?

You mentioned diphtheria.

Yes.

Diphtheria toxin is a classic, unfortunately potent, example.

It targets our own elongation factor, EEF2.

It chemically modifies EEF2, adding an ADP ribose group, which completely inactivates it.

So translocation just stops?

Stops dead.

If EEF2 is inactive, the ribosome can't move.

Protein synthesis halts, and the cell dies.

That's why diphtheria is so dangerous, and why vaccination, like for Edna R's daughter Beverly, is so critical, it prevents the toxin from ever getting a foothold.

Chilling.

Okay, so elongation continues, adding amino acids.

How does it know when to stop?

That must be termination.

Exactly.

Elongation keeps going until one of those three stop codons, UGA, UAG, or UAA, slides into the A site.

And no tRNA matches those?

Correct.

There are no tRNAs with anticoidons for the stop codons.

Instead, proteins called release factors recognize the stop codon in the A site and bind there.

Release factor.

Yes.

And their binding triggers a change.

It causes the peptidyl transferase activity of the ribosome to essentially add a water molecule to the end of the polypeptide chain instead of another amino acid.

Ah, so it cuts the protein free from the last tRNA.

Precisely.

It hydrolyzes the bond, releasing the completed polypeptide chain.

Then everything else falls apart.

The release factors leave, the ribosome subunits dissociate from each other, and the mRNA and the last tRNA is released.

The whole complex disassembles ready for another round.

The brokerage is made.

But wow, that sounds incredibly energy intensive, all those steps.

Oh, it is.

Hugely energy intensive.

Think about it.

Charging each tRNA costs the equivalent of two ATPs.

Then, during elongation, getting the tRNA into the A site costs one GTP and translocation costs another GTP.

So four high -energy bonds per amino acid added.

That's right.

Four high -energy phosphate bonds for every single amino acid incorporated into the chain.

Protein synthesis is one of the most energy demanding processes in the cell.

It's a massive investment.

But the story doesn't quite end there, does it?

When the protein chain just pops off the ribosome?

It's not usually functional right away, is it?

You're absolutely right.

A linear chain of amino acids isn't usually the final product.

There are crucial post -translational events.

First off, efficiency.

Often you'll see multiple ribosomes translating the same mRNA molecule simultaneously.

Like a convoy.

Exactly.

One ribosome starts, gets a little way down, then another one hops on the store codon, then another.

This structure, an mRNA with multiple ribosomes translating it, is called a polysum, or polyribosome.

It's a way to make many copies of the needed protein very quickly from a single message.

Makes sense.

Get more bang for your buck from each mRNA.

Right.

Then, as the polypeptide chain emerges from the ribosome, it needs to fold into its specific, complex, three -dimensional shape to be functional.

This folding isn't always spontaneous.

It needs help.

Often, yes.

Specialized proteins called chaperones, many of which are also known as heat shock proteins, bind to the emerging chain and help guide its folding, preventing it from clumping up or misfolding.

Sometimes specific chemical bonds, like disulfide bonds between cysteine residues, also need to form to stabilize the structure.

Okay.

Folding is key.

What else happens after translation?

Lots of things.

We call them post -translational modifications.

These are enzymatic changes made to the amino acids after they've been incorporated into the chain.

These modifications are absolutely critical for the protein's function, location, or stability.

Like what kind of modifications?

Well, sometimes parts of the protein are snipped off, that's cleavage.

The initial is often removed, or larger precursor proteins like pro -insulin are cleaved to produce the active form, insulin.

Then there are covalent additions of various chemical groups, things like adding acetyl groups or methyl groups.

Hydroxylation adding OH groups to proline and lysine and collagen is vital for its structure.

Carboxylation adds carboxyl groups, important for calcium binding and blood clotting proteins.

Proteins can have fats or lipids attached to anchor them to membranes and crucially phosphorylation.

Adding phosphate groups.

Yes.

Adding or removing phosphate groups acts like a molecular switch, turning the activity of many proteins on or off.

It's a key regulatory mechanism.

Then there's glycosylation.

Adding sugars.

Exactly.

Adding complex carbohydrate chains.

This is especially common for proteins that are going to be secreted out of the cell or embedded in cell membranes or sent to lysosomes.

These sugar chains can affect folding, stability, and targeting.

Targeting, right.

So once a protein is made and folded and maybe modified, how does it get to the right place in the cell or even outside the cell?

It sounds like cellular traffic control.

It really is like a highly organized postal service.

Cells have sophisticated protein targeting or protein sorting mechanisms.

Where a protein ends up depends largely on where it was synthesized and whether it has specific address labels or targeting sequences.

Okay, so where are proteins made?

Two main places.

Some ribosomes float freely in the cytosol.

Proteins made on these cytosolic ribosomes typically stay in the cytosol.

Or they might get imported into the nucleus, mitochondria, or peroxisomes if they have the right targeting sequence.

And the other place.

The other ribosomes are attached to the membrane of the endoplasmic reticulum, making it look rough.

The rough ER or RER.

The RER.

Proteins synthesized on RER -bound ribosomes are generally destined for secretion out of the cell or to become part of cell membranes or to go to organelles within the secretory pathway like the Golgi apparatus or lysosomes.

How does this cell know which proteins should be made on the RER?

These proteins usually have a special signal peptide right at their beginning.

They're interminis.

It's like a little send me to the ER tag.

So what happens when that tag emerges from the ribosome?

As that signal peptide emerges, a complex called the signal recognition particle or

binds to it and the ribosome.

This pauses translation temporarily.

Puts it on hold.

Right.

Then the SRP escorts the whole ribosome complex to the RER membrane, where it binds to an SRP receptor.

Once docked, translation resumes and the growing polypeptide chain starts threading through a channel into the RER lumen, the space inside the ER.

The signal peptide is usually cleaved off once it's inside.

Clever.

So it gets synthesized directly into the ER.

What happens then?

From the ER, these proteins typically travel to the Golgi complex or Golgi apparatus.

Think of the Golgi as the main sorting and processing center.

Like a post office sorting room.

Exactly.

In the Golgi, proteins undergo further modifications, especially to their carbohydrate chains, glycosylation.

And then critically, the Golgi sorts the proteins and packages them into vesicles for delivery to their final destinations, whether that's secretion, the plasma membrane, or lysosomes.

How does it sort them?

More address labels.

Precisely.

A fantastic example is how enzymes destined for the lysosome get tagged.

In the Golgi, they acquire a specific sugar modification called mannose 6 -phosphate.

This M6P tag acts as a specific address label.

Mannose 6 -phosphate for lysosomes.

Right.

There are M6P receptors in the Golgi membrane that recognize this tag and bind to these enzymes, clustering them into vesicles coated with a protein called clathrin.

These vesicles then bud off and deliver their contents to the lysosomes.

And if that tagging goes wrong?

That leads to serious problems.

There's a devastating condition called eye cell disease, or mucolipidosis 2.

It's caused by a defect in the enzyme that adds the mannose 6 -phosphate tag.

So the lysosomal enzymes don't get the label.

Exactly.

Without the M6P label, they aren't recognized by the receptors, they don't get packaged into vesicles for the lysosomes.

Instead, they end up being mistakenly secreted out of the cell.

And the lysosomes are left empty?

Well, they don't get their normal complement of digestive enzymes, so waste products build up inside them, leading to inclusion bodies, that's the eye cell name, and severe developmental issues.

It tragically highlights how crucial correct protein targeting is.

This is related mechanistically to other lysosomal storage diseases, like Tay -Sachs disease that affected JS.

In Tay -Sachs, a specific lysosomal enzyme is made, but it's defective, it can't break down certain lipids, leading to toxic buildup, especially in nerve cells.

These clinical lengths really drive home how vital every step is.

Lisa Ann's Othalassemia Intermedia that's directly about the rate of making the otoglobin protein chain being wrong due to mutations affecting translation.

Yes, exactly.

Errors in synthesis rate or control.

And JS's Tay -Sachs, as you said, a failure in the function of a correctly targeted lysosomal protein.

It all connects back.

What an absolutely incredible journey we've taken today.

From just, you know, letters in the genetic code to these complex functional proteins that literally make life happen.

It's an astonishing biochemical ballet inside every cell.

It truly is.

If you think about the key points, the code read in triplets, the tRNAs as adapters, the ribosome as the factory, the meticulous steps of initiation, elongation, termination, all highly regulated, and then the crucial post -translational folding, modifications and targeting that determine what the protein actually does and where it does it.

And what's really striking is how understanding these details helps us understand health and disease from genetic disorders like thalassemia or Tay -Sachs, where one step is flawed, to how we can cleverly design antibiotics to fight infections by targeting just the bacterial version of this machinery, its fundamental biology with direct clinical impact.

It really makes you think, given all this incredible precision, the multiple error steps built into making proteins.

How resilient is the body to the small errors that must inevitably sneak through?

And what are the ultimate consequences when these complex systems start to fail, maybe with age or disease?

Something to ponder.

Thank you for joining us on this deep dive into the fascinating world of protein synthesis.